Highlights d Different escape mechanisms delineated by lack of adaptive immunity or immunoediting d Non-recurrent clones are immunoedited; progressing clones are immune privileged d Immunoediting and Immunoscore are predictive factors of metastasis recurrence d Parallel selection model describes clonal immunoediting and tumor evolution A longitudinal analysis of clonal evolution of tumors across multiple tissues identifies a parallel selection model that explains the role of immune editing in controlling metastatic growth.
INTRODUCTION
One of the most renowned theories of tumor evolution in the past decades was formulated as an accumulation of driver mutations conferring successive steps of clonal expansion and selective advantage of specific tumor clones (Fearon and Vogelstein, 1990) . Alternatively, a big-bang model described tumor evolution as an initial single clone expansion that is rarely followed by subclonal outgrowth and selective sweeps (Sottoriva et al., 2015) , which implies pervasiveness of the major driver mutations in all tumor cells and clonal robustness to the local microenvironment. More recently, a third model of tumor evolution described the accumulation of mutations under neutral evolutionary dynamics (Williams et al., 2016) . Currently the most widely accepted, the branched evolution model posits multiple co-existing clonal expansions that diverge from a common ancestor and evolve in parallel (Gerlinger et al., 2012) . These four theories reflect tumor cell-centric hypotheses.
Whereas some current models consider metastases to arise from cell-autonomous alterations in the cancer cell genome (Hunter et al., 2018) , alternative views propose that metastatic traits are acquired through the exposure of cancer cells to paracrine signals (Langley and Fidler, 2007; Prendergast and Jaffee, 2007) and factors within the tumor microenvironment (Mlecnik et al., 2014) . However, efforts to elucidate the role of the tumor microenvironment on the metastatic potential of tumor cells have been hindered by the vast diversity of infiltrating immune cells (Bindea et al., 2013) , the extensive interactions between tumor cells and surrounding tissues (Labiano et al., 2015) , and the elusive and dynamic nature of paracrine signals (Finn, 2008) . Murine studies have shown that the immune system prevents the formation of distant metastasis by maintaining a state of dormancy in circulating tumor cells and potentially in tissue micrometastases (Koebel et al., 2007; Schreiber et al., 2011) . In humans, our previous data demonstrated a major role of cytotoxic and memory T cells in predicting survival of cancer patients (Galon et al., 2006) , in preventing early metastatic dissemination (Pagè s et al., 2005), and in protecting against seeding of distant metastasis (Mlecnik et al., 2016b) . Very few studies only recently have addressed the role of the immune system in metastatic heterogeneity (Jimenez-Sanchez et al., 2017; Zhang et al., 2018) . However, the metastatic seeding and evolutionary clonal dynamics under immune pressure remain elusive in the absence of a longitudinal disease followup (Caswell and Swanton, 2017; Lloyd et al., 2016) . An improved understanding of the processes leading to metastatic invasion and development is required to devise novel treatment paradigms for late-stage tumors.
We hypothesized that metastatic progression and clonal evolution of tumor cells underlie Darwinian selection of tumor clones mediated both by tumor-intrinsic characteristics as well as extrinsic immune pressure. Tumor cell variants having low immunogenicity and resistance to immune attack are thereby selected and proceed to the equilibrium phase, while highly immunogenic tumor clones are eradicated in the elimination phase. Indeed, the existence of cancer immunoediting has been demonstrated both in mouse models (Matsushita et al., 2012) and in human primary tumors, for missense and frameshift mutations (Mlecnik et al., 2016a) .
Here, we sought to determine how immune pressure shapes metastatic evolution based on 11-year-long spatiotemporal follow-up of metastatic colorectal cancer (CRC). We characterized the evolving metastatic genome and the immune microenvironment and then described the juncture of immune surveillance and escape and clonal seeding and progression. Herein we propose a parallel selection model of tumor evolution during the metastatic process depending on the strength and quality of the local immune response.
RESULTS

A Framework of Metastases Evolution under Immune Pressure
We closely examined a rare, longitudinal dataset of 31 metastases from two cases of stage IV CRC with exceptionally long survival. The progressive course of the metastatic diseases was followed by sampling spatiotemporally distinct sites, within and across metastases of two patients, P210 and P45 (Figure 1A) . Accounting for a total of 36 samples, the fully resected primary tumors, synchronous, and metachronous metastases were characterized extensively at genomic level and with regards to the tumor microenvironment. This allowed the evaluation of intra-metastasis, inter-metastasis, and interpatient genomic and immune heterogeneity (Figure 1) .
The immune microenvironment of the curatively resected metastases was first investigated using single-plex immunohistochemistry (IHC) staining and digital quantification for several immune markers of major lymphocytic lineages ( Figure 1B) . Three metrics were used to quantify the immune infiltrates: whole-slide immune cell densities (WS), densities of the three most-infiltrated tiles or hotspots (HSs), and the Immunoscore derived from the CD3 + /CD8 + T cell densities in the center of the tumor (CT) and its invasive margin (IM). In addition, we charted the spatial distribution of the immune cells in the tumor microenvironment based on multispectral imaging with a 7plex panel of immunofluorescent markers ( Figure 1C ).
Next, we performed whole-exome sequencing of matched blood samples, resected primary, and consecutive metastatic samples. The total number of somatic mutations (coding and non-coding) per sample ranged over one order of magnitude for patient P210 (221-2705) , while a narrower and steadier distribution was observed for patient P45 (560-1130, Figure 1D ). The mutational load was associated neither with metastasis location nor with therapeutic regimen. Strikingly, most of the coding mutations (>76%) were unique to one metastasis. Thus, both patients had high inter-metastatic genetic divergence, expressed by a small percentage of shared coding and non-coding mutations (18% in P210, 16% in P45, Figure 1E ). Few mutations were found only in the primary tumor and in one metastasis (n = 303 [3.3%] in P210, n = 23 [0.3%] in P45). For each patient, we then plotted the frequency of mutational recurrence among the metastases, showing the number of point mutations that are unique for one sample or shared by 2, 3, 4, ., n metastases ( Figure 1F ). There was no difference in the frequency of recurring mutations between the two patients ( Figure 1F , two-sample Kolmogorov-Smirnov test, p = 0.26). Strikingly, no single mutation was shared in more than 12 metastases for P210 (n = 17 samples), whereas only 10 mutations, including missense (GOLT1B, DIDO1, POLR1D, ZNF727, GRIN2A, NFATC2), silent (MOS, STK36), splice-variant (RAP), and intronic (PTGIS), were shared among all (n = 18) metastases of P45.
The Metastatic Evolvogram Identified Multiple Routes of Dissemination in CRC A phylogenetic tree was reconstructed based on the concordance of nonsilent point mutations among the primary and metastatic samples (Figure 2A ), using the Parsimony Ratchet method (Murugaesu et al., 2015) . Overall, the samples from the A) Anatomical map of biospecimen collection sites in two CRC patients, P210 and P45. Two consecutive slides were assayed from the metastasis M8 (a and b, P45). Multi-regional resection specimens were collected from a large necrotic area (M07n) and its surrounding tumor tissue in M07, as well as from one bulky metastasis, M10 (four sites b1-4, size 25 mm) in patient P210. (B) Whole-slide digital scans with immunohistochemical staining of formalin-fixed paraffin-embedded cross-sections were annotated for the center of the tumor (CT), and the invasive margin (IM), and then separated into tiles for automated quantification of whole-slide (WS) and hotspot (HS) densities. (C) Representative composite fluorescent images for seven biomarkers. (D) The total number of coding and non-coding mutations is shown as stacked bars colored according to the recurrence status of the mutations: sample-specific mutations (orange), and mutations that recur in at least two samples, either including the primary tumor (green) or only metastases (blue). The clustered mutations were visualized so that the y axis tracks the cumulative order of each mutation (bottom). (E) The Venn diagrams summarize the fractions of shared and unique mutations for each patient. (F) Frequency of mutation recurrence during metastatic progression. same metastatic location were phylogenetically closer and shared more mutations compared to anatomically separate metastases. In addition, previously known cancer driver genes were frequently located on the branches of shared mutations. Even so, there were no conserved early driver events still detectable for patient P210 (trunk = 0), regarding nonsilent point mutations, as well as copy-number variations ( Figure S1A ). Contrary to P210, in the patient P45, the trunk comprised six non-synonymous mutations without solid evidence for cancerdriving propensity in the literature span. APC and TP53 harbored conserved, truncating mutations, previously described as some of the initial events in colorectal carcinogenesis (Gerstung et al., 2011) . We next inferred the origin of each metastasis based on the similarity of the coding mutation profiles. A parent-child relationship was defined by the highest Jaccard similarity coefficient. The routes of metastatic dissemination were then visualized with a tree representation of the metastases clade, from the time of diagnosis to the last follow-up ( Figure 2B ). In the patient P210, the tumor site M10-b3 was an integral part of the bulky metastasis M10, but it had a different origin than the remaining regions sampled from the same metastasis (M10-b1, -b2, and -b4), indicating that M10 was a result of multi-step colonization. Furthermore, there were indications of metastasis-to-metastasis spread within and across organ boundaries. Metastases could provoke seeding (1) in one or multiple instances of recurrence (e.g., M10-b1 and M11 in P210), (2) in the same time interval or at different time intervals (e.g., M7 and M3 in P45), (3) within the encompassing organ or at a distant anatomical site (e.g., M3 in P45). Of note, in both patients, only one of the synchronous metastases expanded the metastatic lineage; M06 in P210 had four recurrences at two different time points and two different locations, while M03 in P45 had six recurrence events, three times within 4.4 years at two distinct anatomical sites. These observations suggest that some metastases were more aggressive than others.
A
To compare aggressive and regressed metastases, we analyzed the tumor mutational spectrum, copy-number information, clonal composition and genealogy, and immunoediting (observed/expected neoantigen rate). First, known patterns of chromosomal instability (CIN) with amplification of chromosomes 7, 13, 20, 8q, 17q, and deletion of chromosome 18, 8p, and 17p were found in multiple metastases ( Figure 3A ) (Mlecnik et al., 2016b) . Overall, higher ploidy and higher chromosomal instability were observed in the patient P45 compared to P210 (p = 0.009 and p = 0.001, respectively, Mann-Whitney test). Interestingly, the primary tumors of both patients were near-diploid, but aneuploidy was frequently observed among their successive metastases ( Figure S1B ). Additional patterns over time were exhibited by decreasing mutation inter-metastasis heterogeneity (IMH) ( Figure S1C , not CNA IMH) and increasing immunoediting scores ( Figure S1D ).
We followed the changes in genomic imprint also to reconstruct the tumor architecture of each sample and to track its clonal dynamic over time. The cellular prevalence of a given somatic mutation was estimated by integrating sequencing coverage with inferred parental copy numbers and estimated tumor purities (STAR Methods). Under the assumption that mutations at similar time points of the clonal phylogeny are present at similar cellular prevalence, a cross-sample Bayesian clustering approach was applied to infer tumor clones (Roth et al., 2014) . For both patients, 12 different tumor clones that developed at a certain point over the follow-up timeline surpassed a clone detection threshold of 10% ( Figure 3B ). The metastases with similar clonal compositions were closely related anatomically, temporally, and phylogenetically.
To infer the hierarchy of the tumor clones, we further applied a genetic algorithm to the cellular frequencies and mutation clusters ( Figure 3C ; STAR Methods). The common clonal ancestor, i.e., the founder clone of the primary tumor was not detected, likely due to limited sampling of the primary tumors. However, the most persistent clones during disease progression were traceable back to the primary tumors. In both clinical scenarios, the origin of the synchronous metastases was subclonal. Rather than the major clone, minor subclones from the primary tumor fueled a sequence of recurrence events and (1) reinstituted into dominant clones in metastatic samples (e.g., clone 2 in P210:M07-9, clone 1 in P45:M02-16) and (2) often co-evolved with new clones (P210:M10-15) or gave rise to new divergent clones (P210:M07n, P45:M11-12). Based on the reconstructed subclonal hierarchy, we found evidence of monophyletic dissemination, with both monoclonal (e.g., M07-9 in P210) and polyclonal (e.g., M01 in P45) seeding patterns ( Figure S2C ). In addition, polyphyly was tracked in both patients, having different subclones disseminated at different time points, and in separate organs (M06 of P210, M03 of P45).
Despite the indications of a linear evolution model, there were elements of parallel evolution, such as the high level of genetic divergence between primary and metastatic tumors. Moreover, parallel evolution of TP53 was observed for the metastasis M06, where two mutated loci were detected in two different clones, the persistent clone 1 and the eliminated clone 12 of patient P210. Ongoing evolution was manifested by unique tumor clones in several metastases (e.g., clone 8 in M06, P45, Figure S2C ). Furthermore, the presence of different tumor clones in the spatially different samples of M10 in the patient P210 demonstrated intra-metastatic clonal heterogeneity.
Hence, the genomic structure of each tumor was elaborated by an extensive list of features ( Figure 3D ). First, different types of mutations correlated strongly with mutational burden , each sample was plotted and annotated with a color code for location, Immunoscore (WS, HS), tumor size, and time lag from the primary malignancy (synchronous and metachronous). The time intervals between surgical interventions (represented by ranging line widths) and the treatment information are shown alongside each phylogenetic tree. The site of origin for each metastasis was determined based on the highest mutational concordance and represented by a link between each parent-child pair. (r > 0.87, p < 0.001, Table S1 ), while immunoediting showed a weaker correlation (r = 0.49, p = 0.05). Immunoscore and ploidy were not associated with mutational load (Table S1 ). Moreover, the two patients exhibited several differences on genomic level. The ratio of transitions and transversions was significantly higher in P210 compared to P45 (p < 0.05). In contrast, more epitopes, drivers, and mutations (missense, silent, immunogenic), higher ploidy, and immunoediting scores were found in P45 (p < 0.05). While the mutational IMH was higher in P210 compared to P45 (p = 4e-05), the copy-number IMH was lower (p = 0.001). Even more, major differences were found among the metastases of the same patient. Together, the metastatic evolvogram displayed clonal dynamics and heterogeneity, where some clones did not disseminate, while others persisted; thus, some metastases were able to colonize, whereas others didn't recur.
P45 P210
The Immune Microenvironment in Progressive Metastatic CRC To elucidate the immune contexture, we interrogated tumor infiltrating lymphocytes (TILs) through single-plex IHC, multispectral imaging, and multiplex immune gene expression. Overall, the intra-patient variation of each phenotype was relatively large ( Figure 4A ). The most abundant immune phenotype in both patients were T cells within the invasive margin (IM, 334-3,218 cells/mm 2 , median 1,494), which correlated with the single-plex IHC densities (r = 0.74, p = 8eÀ6, 268-3,473 cells/mm 2 , median 1,895). The lowest densities were found for CD3 + Ki67 + cells in the center of the tumor (CT, 0-14 cells/mm 2 , median 0.06) and the invasive margin (0-95.7 cells/mm 2 , median 0.77). Moreover, no differences in cell densities within the tumor tissue (CT) and only B cells in the stroma were significantly higher in P210 compared to P45. Similarly, higher Immunoscore values were measured among the metastases of P210 (p = 0.005, Mann-Whitney test). Interestingly, even some of the latest metastases had high Immunoscores (e.g., M14 and M15 in P210 at 8.1 years, and M12 in P45 at 3.2 years since diagnosis). Overall, there was no association between the Immunoscores of the parent and the child metastases.
To characterize the tumor microenvironment configuration, we examined the spatial patterns of every pair of cell phenotypes, using the topographic information derived for multispectral imaging. We measured the average mutual neighbor distance to describe potential interactions between each pair of cell phenotypes ( Figure 4B ). The shortest distances were observed for CD3 and CD3 + Ki67 + in IM (4.7-18.2 mm, mean 10.2) and expectedly for CK + (cytokeratin + ) and CK + Ki67 + in CT (5.3-48.1 mm, mean 13). We found little variation in mutual neighbor distances between the two patients. On average, there were no differences for any phenotype pair in CT, and only between PD-L1 and CD20 in IM there were shorter distances in the metastases of P210 ( Figure 4B ).
We then identified and quantified the clonotypes for T cell and B cell populations, using the raw exome sequencing data (Figure 4C) . In both patients, we obtained a diverse pool of T cell receptor (TCR)-a sequences (P210 1-25, median 9.5; P45 1-19, median 5) and a lower number of B cell clonotypes (immunoglobulin K [IgK], 1-6, median 2). Rarely were the same TCR-a and TCR-b V-J recombinations shared among metastases, having Va1-Ja33 from P210 as the most common (n = 7). Furthermore, the TCR-a diversity expressed as the number of different sequences of the complementarity-determining-region 3 (CDR3) strongly correlated with TIL densities and Immunoscore, as evaluated by single-plex and multiplex IHC, and immune gene expression ( Figure S3 ). Therefore, comparison between the patients showed little disparity with regards to averaged immune infiltrate densities and spatial distribution (Figures 4A and 4B) . However, at the same time, there was a confounding diversity across spatially and temporally diverse tumor microenvironments of the same patient concerning their extent of immune infiltration and T cell repertoires.
Different Escape Mechanisms Delineated by Immune Status and Immunoediting
We evaluated the immunoediting score individually for each metastasis as the ratio of observed to expected immunogenic mutations per nonsilent mutation (Mlecnik et al., 2016a; Rooney et al., 2015) ( Figure 5A ; STAR Methods). A higher-than-expected immunogenic rate indicated absence/lack of immunoediting and immune tolerance (score >0.8, n = 24, Figure S4A ). Several metastases displayed evidence of major immunoediting, i.e., a lower frequency of immunogenic mutations than expected (score %0.8, n = 7). Furthermore, by plotting the immunoediting score (Yes/No) and the corresponding Immunoscore values (Hi/Lo), we defined four categories of metastases (HiYes, HiNo, LoYes, and LoNo, Figure 5A ). Strikingly, none of the metastases corresponded to the group of low Immunoscore and immunoediting (LoYes). Supporting the notion that weak adaptive immunity is insufficient for immunoediting to occur, low Immunoscore and immunoediting were mutually exclusive (LoNo, n = 18). On the contrary, immunoediting was observed exclusively in metastases with inflamed T cell phenotype and high Immunoscore (HiYes, n = 7), and neoantigen depletion resulted from an active immune selection. Nevertheless, 54% of the 
metastases with high Immunoscore were immunoedited. This result demonstrates that immune infiltration is necessary but not sufficient for immunoediting to occur and that immunoediting occurs in humans at the metastatic stage.
Interestingly, the metastases with low Immunoscore and no immunoediting were more prone to recurrence and gave rise to at least one child metastasis in 64% of the cases, as opposed to, only 8% of metastases with high Immunoscore (p = 0.058, Fisher's exact test). In six unedited metastases, there was a loss of heterozygosity (LOH) in at least one human leukocite antigen (HLA) allele that could be attributed to lack of immunoediting in some metastases (Figures S1A and S1E). Moreover, unedited metastases were characterized by higher ploidy levels (r = 0.55, p < 0.001, Figure 5B ). LOH in a chromosome 4 region containing the gene IL15 was another tumor-intrinsic feature distinctive for the absence of both immune control and immunoediting (LoNo) (Fisher's exact test, p = 0.05, Hi versus Lo Immunoscore). On the contrary, the immunoedited metastases with high Immunoscore were differentiated by increased densities of memory T cells (CD45RO) and proliferating T cells (CD3 + Ki67 + ), as well as higher mutation IMH (mIMH), compared to unedited metastases (p < 0.05) ( Figure 5C ). Furthermore, immunoediting had the strongest correlation with various T cell phenotypes associated with cytotoxicity, adhesion, Th1, Tfh, CD8 cells, the chemokine CCL2, cytokines, and immune checkpoints ( Figure S3 ). Weaker and significant correlations could also be seen for neoantigen burden but not for coding mutations.
Identification of a group of metastases with no immunoediting in the presence of TILs (HiNo, n = 6) revealed several actions of tumor-extrinsic escape. Increased densities of FOXP3 + cells (p % 0.02, increase over HiYes: 442-527 cells/mm 2 ) and PD-L1 + cells (p % 0.01, increase over HiYes: 11-41 cells/mm 2 ) in CT and IM delineated the HiNo group ( Figure 5C ). Higher TCR-a diversity, as measured by the number of different clonotypes, could indicate absence or scarcity in T cell clonal expansion in this group (5.5-fold increase in HiNo versus HiYes, major and significant differences versus LoNo) ( Figure 5D ) (Jimenez-Sanchez et al., 2017) .
Beyond immune cell densities, we also explored the spatial distribution of different cell phenotypes across whole-tumor resections. We measured mutual neighbor distances between each pair of cell phenotypes and calculated a cross-type cumulative distribution of the nearest neighbor distances, G(r) (STAR Methods). We discerned differential spatial organization for CD3 T cells and proliferating tumor cells (CK + Ki67 + ) among the distinct Immunoscore-editing groups ( Figure 5E ). The spatial localization of proliferating tumor cells CK + Ki67 + and CD3 + T cells for representative metastases was illustrated with com-posite fluorescent images ( Figure 5F ) and cumulative distributions of cross-type distances, G(r) ( Figure 5G ). Indeed, the HiYes group had shorter average mutual neighbor distances between CD3 + and CK + Ki67 + cells ( Figure 5H ). Moreover, within HiYes metastases, on average one-half of the proliferating tumor cells in CT had a surrounding CD3 + cell(s) within a radius of 25 mm ( Figure 5H ). Besides that, for the HiNo metastases, we found a higher percentage of T cells (CD3 + ) and tumor cells (CK + ) that have the nearest PD-L1 within a radius of 25 mm, in CT and IM, respectively. Therefore, beyond the quantitative immune characterization, the immune atlas revealed novel, potential tumorextrinsic escape mechanisms. Thus, immunoedited metastases had high Immunoscore and a short distance between T cells and proliferating tumor cells, whereas non-immunoedited metastases had increased densities of FOXP3 + T cells, increased PD-L1 expression, and significant proximity of T cells to PD-L1 + cells.
Impact of Immunoscore and Immunoediting on Metastatic Disease Progression
To understand the tumor characteristics related to its risk of recurrence, tumor clones were assigned into three groups depending on whether they had been transmitted to a child metastasis (persistent, eliminated, and early non-recurrent, STAR Methods). We compared the persistent and eliminated tumor clones by several genomic features, including the Dn/Ds score as an indicator of selective pressure on nonsilent mutations (Table S2 ). None of them was associated with the recurrence status of the tumor clones. Having observed above differential intra-metastatic immunogenicity, we calculated an immunoediting score for each tumor clone individually. Strikingly, immunoediting was more frequently found in eliminated tumor clones, whereas the absence of immunoediting was a feature of persistent clones (Fisher's exact test, p = 9.7 3 10 À8 ) ( Figure 6A) . Notably, only one persistent clone, clone 2 from P45, presented with immunoediting. In fact, this clone had only one immunogenic mutation located within the gene ZDHHC11, which had a negligible level of expression (median = 0.9 transcripts per million [TPM], interquartile range [IQR] = 1.3), according to public RNA sequencing (RNA-seq) of primary CRC (n = 626). Interestingly, the major clone (clone 4) was immunogenic, immunoedited, and eliminated, without reappearance in any consecutive metastases. Furthermore, immune selection separated persistent from eliminated clones (area under the curve [AUC] = 0.89, p < 0.0001) better than positive selection (Dn/Ds score, AUC = 0.59, p = 0.52) ( Figure 6A ; Table S2 ). Immunoediting was the best predictor of tumor clone recurrence (AUC = 0.89), having an even better performance without considering clone (B) The spatial distribution of the immune cells in the two patients, P210 and P45, was compared by the distances between mutually nearest cells. All possible phenotype pairs were tested, and the significant differences were highlighted in black at false discovery rate (FDR) <0.1, or gray otherwise (Wilcoxon rank-sum test, p % 0.05, Benjamini-Hochberg adjustment). (C) TCR repertoire derived from raw exome-sequencing data. The identified pairs Va-Ja and Vb-Jb genes were shown with their estimated TCR clonotype fractions (z axis) for each sample (y axis). The most commonly found TCR-a and TCR-b chains were highlighted for each patient. 2 of P45 (AUC = 0.98). Similar results were observed in an ovarian cancer case with metachronous metastasis ( Figure S5 ). Different clones from the same metastasis had different immunoediting scores ( Figures S2B-S2D ). Across different metastases, however, unedited clones remained unedited. Moreover, the core of the metastasis M07, populated with dying tumor cells and T cells, had one prevalent tumor clone, clone 6, which was not found in the invasive margin of the same metastasis ( Figure S2B ). We studied the immunogenicity of these mutations and found that clone 6 from the necrotic area was immunogenic, contrary to clone 2 in the invasive margin that had no immunogenic mutations. These observations provide evidence for differential immunogenic potential of tumor clones within one metastasis.
Finally, we asked which of the parameters that manifested mechanistic implications so far in our study could also have clinical relevance. We performed univariate analysis on a series of 22 clinical, genomic, immune, and spatial parameters (Table  S3 ). We reasoned that each metastasis should be approached as a different disease/case, not only because of the large IMH but also because of their differential dissemination potential. The two best predictors of favorable clinical outcome were immunoediting (hazard ratio [HR] = 0.16, p = 0.01) and Immunoscore (HR = 0.13, p = 0.03, Figure 6B ). Covariate selection on the significant parameters from the univariate analysis yielded the best multivariate regression model with four selected covariates ( Figure 6C ), one of which, the mutual neighbor distance between CK + Ki67 + and CD3 + cells in CT, was not significant in the multivariate model. According to the model, lower Immunoscore, absence of immunoediting, and higher metastasis burden had an adverse impact on recurrence-free survival. The relation between the immune system and tumor dissemination over time was evaluated by superimposing immunoediting and Immunoscore on the phylogenetic tree of metastases ( Figure 6D ). This illustrates the local control (smaller size) of the metastasis and the protective effect of Immunoscore in preventing recurrence. Thus, metastasis progression and time to recurrence were dependent upon mechanistically linked immune parameters (schematic abstract, Figure 6C ).
We then generated a predictive time-to-event model of metastatic cancer evolution to estimate the probability of recurrence based on the selected covariates. The clinical outcome was considered until the last follow-up on January 2016, when both patients were in complete remission and disease free. The model was built blindly to the clinical outcome after January 2016. Cumulative recurrence probabilities over time were calculated for each type of metastasis ( Figure 6E ). Thus, independently on time from detection (TFD), the metastases with the highest recurrence probability had a large size, low Immunoscore, and no immunoediting. Inversely, the lowest risk group comprised immunoedited metastases with high Immunoscore and small burden. The recurrence risk is particularly pronounced in the first 2 years since detection.
The estimates from the predictive model were then applied on each metastasis to quantify its probability to recur from the last follow-up onward ( Figure 6F ). According to the predicted outcome, almost all metastases from patient P210 have surpassed the time of recurrence risk, whereas for patient P45 there were several high-risk samples, particularly the latest metastases M15 and M16. The model predicted less than 35% probability for P210 to have a new recurrence event as of January 2018. Indeed, P210 is still in complete remission to date. In contrast, a high risk of relapse was estimated for P45. The two peritoneal metastases M15 and M16 have a probability of 95% to recur before January 2017, and a 99% recurrence probability before January 2018. In agreement with the model predictions, in April 2016 the patient P45 was diagnosed with a relapse, particularly with several unresectable metastatic lesions in the peritoneum and the liver.
Two independent validations were performed. First, we applied our prediction model a recently published case study of one ovarian cancer patient with 4 metachronous metastases (all resected simultaneously several years after their detection) (Jimenez-Sanchez et al., 2017) and predicted a high probability for a first recurrence ( Figure S5 ). Second, assuming that progression is influenced by immune pressure in both metastatic and primary tumors, we analyzed primary CRC (n = 132) to predict the first event of metastatic dissemination. We observed an association between immunoediting and decreased risk of metachronous recurrence ( Figures S6A-S6C ). Moreover, our prediction model stratified low, intermediate, and high-risk tumors, which were confirmed to have significantly different recurrence rates ( Figure S6D ).
DISCUSSION
A critical step toward tailoring therapies for long-term diseasefree survival is to decipher the resilience of certain clones and (G) Cumulative distributions of cross-type distance from CK + Ki67 + to the nearest CD3 + evaluated in an area with radius r. The theoretical curve, G theo (r) with its confidence envelopes illustrates random sample distribution. (H) All cell phenotypes were compared pairwise by mutual neighbor distances and nearest-neighbor distance distribution functions (G km ) at 25 mm. Only significant associations were visualized (rank-based non-parametric test, post hoc multiple comparison, ***p < 0.001, ** 0.001 R p < 0.01, * 0.01 R p < 0.05). See Figure S3 . metastases. The tumor cells and its microenvironment communicate intricate fostering and restraining signals. Therefore, it is of utmost importance to understand metastasis evolution under immune pressure. Having a relatively large number of completely resected metastases per patient over an exceptionally long survival period (across more than 11 years), we investigated the drivers of recurrence and followed the evolutionary dynamics on matched spatiotemporally distinct genomes. We determined the origin of each metastasis and each clone and distinguished recurrent from non-recurrent metastases, as well as eliminated from persistent clones. Comparison of these metastases/clones revealed several findings on the power of the immune system in metastasis recurrence. First, anatomically and temporally distinct metastatic sites exhibited different clinical responses, genomic architectures, and immune activities. Hence, each metastasis is a disease on its own and metastatic disease cannot be averaged per patient. Coexistence of different immune microenvironments in the same individual conforms to previous findings in multiple metastatic sites of ovarian cancer (Jimenez-Sanchez et al., 2017) . In addition to that, here we observed distinct tumor-immune ecosystems in both space and time, remarkably, between parent and child metastases, and even within the same metastasis. The fact that neither a single biopsy nor one metastasis is sufficient to generalize the tumor setting poses daunting challenges for any clinical modality.
Second, we described the clonal evolvogram of metastatic progression. Understanding the trajectories of metastatic spread could be a powerful tool to estimate the risk of metastasis and could have profound implications for patient management (Turajlic and Swanton, 2016) . We traced multiple routes of dissemination, including multistep colonization, polyphyly, and polyclonal seeding with genetic evidence for both linear and parallel progression, all within a single patient. However, whether a tumor clone is prone to dissemination remains an open question when considering genomics features solely. We could detect traits of tumor-intrinsic selective pressures over the disease course, such as recurrent inactivation of TP53 and decreasing mutational IMH. Despite that, many tumor clones did not carry known driver mutations. Also, not a single driver or passenger mutation was present on all metastases in the patient P210.
Third, we therefore analyzed the immune microenvironment in relation to tumor clones through space and time. Several obser-vations indicated that immunoediting was imprinted in the metastatic genome. Of note, multiple lines of therapy were administered to the patients, but immunoedited clones and metastases were observed independently of chemotherapy exposure and absence of immunoediting could also be detected upon therapy response. We demonstrated a critical heterogeneity of clonal immunogenicity and immunoediting within one metastasis. The immunoediting score, rather than the mutational load, was associated exclusively with an active immune response, implying a predictive potential for immunotherapy. Even more, branched tumor evolution could be traced back to a failure in immune surveillance by immune-escaping clones. The eliminated clones were immunoedited. The tumor clones that persisted and progressed were immune privileged, either unedited or nonimmunogenic. This finding reveals for the first time the relationship between clonal seeding and immune surveillance and has significant implications for therapy. It shows that the persisting cells are identifiable and thereby therapeutically targetable. Targeting clonal neoantigens could prevent recurrence by aiming at the persistent, unedited tumor clones that retain immunogenic mutations. In support of this, a durable clinical benefit has been associated with T cell reactivity against clonal neoantigens previously observed in advanced non-small cell lung cancer (NSCLC) (McGranahan et al., 2016) . Persistence of tumor clones without any immunogenic mutations urges the need for alternative strategies, such as perturbing the DNA mismatch repair machinery to induce genomic instability of tumor cells and increase the burden of neoantigens (Germano et al., 2017) .
Fourth, while we could detect a potent immune activation and high Immunoscore even later in the disease timeline, the overall decreasing trend of immunoediting over time implied acquisition of escape mechanisms. Indeed, aneuploidy was associated with absence of immunoediting. Increasing evidence suggests that chromosomal instability can be an early driver event of metastasis (Wang et al., 2014) before the bulk of mutations are acquired, as it appears in the patient P45. This could result in a diluted concentration of neoantigens and a competitive advantage of self-peptides for antigen presentation, as recently hypothesized (Davoli et al., 2017) . In this context, recruitment of surveilling immune cells would be silenced and accordingly immunoediting would be undetectable (LoNo). Moreover, we identified unedited metastases with high immune infiltration (HiNo) that also had high ploidy. We believe that, in this case, Figure 6 . The Impact of the Immunoscore and Immunoediting on Metastatic Recurrence (A) The tumor clones were assigned into three groups depending on whether they recur (STAR Methods). Each clone is represented as one point, individually for each metastasis. The blue line was set at the cutoff value of 0.8 (see related Figures S2A and S4A) . The performance of the immunoediting score and additional mutational parameters in classifying the two recurrence groups is illustrated as receiver operating characteristic (ROC) curves and their respective AUC values. *Clone 2 in the patient P45 (green) has only one immunogenic mutation with negligible expression levels in primary CRC. (B) Kaplan-Meier curves for univariate recurrence-free survival according to immunoediting (left) and Immunoscore (right) (see related Table S3 ). (C) The table lists the covariates selected for multivariate analysis out of several genomic, pathological, and immune features. Akaike information criterion (AIC) values were shown for each multivariate model excluding the corresponding variable. The hazard ratios (HRs) describe the final multivariate model, where either the first or multiple recurrence events were considered. Statistical significance was highlighted in bold, and a graphical summary of the model was illustrated. (D) Superimposition of the three parameters associated with recurrence (immunoediting, Immunoscore, tumor size) on the parent-child metastasis tree. (E) A predictive model of metastasis recurrence was generated based on immunoediting, Immunoscore, and metastasis size, assuming time-dependent probabilities (TFDs). The plot shows the cumulative probabilities of recurrence over time estimated for different parameters. (F) The predictive model was applied to each sample to estimate its recurrence probability, starting from the last follow-up time (AIC, Akaike Information Criterion; PHA, proportional hazards assumption; CI, confidence intervals; TFD, time from detection; TTR, time to recurrence). See Figures S2, S5 , and S6. chromosomal instability was a later event after the tumor cells were already loaded with neoantigens. Upon a sufficiently strong neoantigen signal, the immune cells could be recruited, but restrained by immunosuppression, resulting in undetectable immunoediting. Indeed, the absence of immunoediting in the presence of TILs (HiNo) revealed several escape mechanisms, including increased densities of immunosuppressive cells and segregation of immune from tumor cells. Thus, we propose that the immune contexture and metastasis immunoediting mirror the temporal order of chromosomal instability.
Finally, the absence of editing was an independent prognostic factor for recurrence, together with Immunoscore and metastasis size. We generated a predictive model of metastatic cancer evolution and correctly predicted the absence of metastatic recurrence risk for P210 and a high risk for P45. It will be important to further validate our findings longitudinally in a large independent cohort presenting with multiple metachronous metastases and long-term survival. However, we demonstrated the possibility to identify the metastases with the highest recurrence probability, so that the treatment could be adjusted according to their acquired escape mechanisms.
In conclusion, we showed evidence that the immune system influences tumor heterogeneity and sculpts clonal evolution. Our duality tumor-immunity model of human cancer metastases proposed that the development of tumor clones is linked to the intra-metastatic immune microenvironment via the immunoediting process. In contrast to the four existing tumor-cell centric models, we divulge here a parallel-multiverse immune selection model of tumor evolution during the metastatic process. These novel insights have several notable implications and may change the understanding of cancer evolution.
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METHOD DETAILS
DNA Sequencing
Whole exome sequencing libraries were prepared and captured using the kit SureSelect DNA -SureSelectXT Human All Exon V5 (Agilent Technologies) following manufacturer's instructions. The DNA library with 150bp paired-end reads was sequenced with Illumina HiSeq technology (Sidra Medicine, Doha, Qatar). The average sequencing coverage of all samples was 180X (one sample had low average target depth of 53X). The reads were mapped using the bwa aligner against the GRCh37.75 human genome annotation that additionally includes the hs37d5 decoy sequences and human herpesvirus 4 type 1 sequence. Due to insufficient DNA quality, three synchronous liver metastases (M01, M02, and M03) of patient P210 and one from P45 (A1) were not subject to sequencing. Additionally, targeted sequencing of frequently mutated cancer genes was performed with Ion AmpliSeq TM Cancer Hotspot Panel v2 from FFPE tissue sections, surveying hotspot regions of 50 oncogenes.
IHC
Formalin-fixed paraffin embedded (FFPE) tissue sections (5mm) from resected metastases and primary tumors were stained for immune cells from the major lymphocytic lineage. Two automated slide staining systems were used, Ventana Benchmark and Discovery CT (Roche), with the Ultraview Universal DAB IHC Detection Kit and ChromoMap DAB kit, respectively. The following primary antibodies were used: CD3 (clone 2GV6, Ventana), CD8 (clone 4B11, Dako), CD45RO (clone UCHL1, Dako), CD20 (clone L29, Dako), and FOXP3 (clone 236A/E7, Abcam). All slides were scanned using a Hamamatsu NanoZoomer at 20x magnification (NanoZoomer 2.0-HT), and microscopic images of full tissue sections (whole slides, 0.46 mm per pixel) were automatically obtained for large-scale TIL quantification.
Whole slide digital scans were then analyzed using a specially developed Immunoscore module integrated into the imaging software Developer XD (HalioDx, Definiens) . The CT and the invasive margin (IM) regions were manually outlined. The IM was defined as the region of 500 mm width on each side of the border between malignant cells and adjacent tissue. Using a grid of tiles, we quantified the whole slide (WS) immune densities as the average number of positive cells per unit of tissue surface area (mm 2 ) per tile (global quantification). The three most infiltrated tiles in CT and IM are used to calculate the HotSpot (HS) densities.
The immunoscore was calculated from two consecutive slides, stained with CD3 and CD8. The densities in the CT and IM regions were compared to a large Immunoscore database of liver and lung metastases from CRC (Mlecnik et al., 2018) , and the values were normalized as percentiles. The Immunoscore percentile is the mean of the four percentiles obtained for the two markers (CD3, CD8) in the two regions (CT, IM). Due to lack of tissue material, the Immunoscore of the primary tumor in P210 was not determined.
To estimate the Immunoscore percentile in the ovarian cancer dataset, we used the IHC measurements provided in the original study (Jimenez-Sanchez et al., 2017) and transformed them into percentiles using a larger set of ovarian cancers (Zhang et al., 2018) .
Multispectral imaging 4-mm-thick FFPE tissue slides were deparaffinized in clarene, rehydrated through an ethanol gradient ending with a distilled water wash and fixed in NBF (10% neutral buffered formalin) for 20 minutes. Antigen retrieval was performed via microwave treatment (MWT) in antigen retrieval solution pH6 or pH9 (AR6 or AR9) depending on the target being detected. At each of the 6 cycles of staining, protein blocking was performed using Protein Block Serum-free (Dako) for 15 min, and primary Abs anti-CD3 (Dako M7254 clone F7.2.38), anti-FoxP3 (CST 98377S clone D2W8E), anti-CD20 (Dako M0755 clone L26), anti-PDL-1 (Biocare Med ACI3171A, C clone Cal10), anti-Ki67 (Dako M7240 clone MIB-1) and anti-pan cytokeratin (Dako M3515 clone AE1/AE3) were incubated for 30 min at room temperature. Next, incubation with HRP Labeled Polymer mouse or rabbit (Dako EnVision+ System-HRP Labeled Polymer) was performed at room temperature for 15 min followed by TSA opal fluorophores (Opal 520, Opal 540, Opal 570, Opal 620, Opal 650 or Opal 690) incubation for 10 min. MWT was performed at each cycle of staining to remove the Ab TSA complex with AR solution (pH 9 or 6). At last, all slides were counterstained with DAPI for 5 min and enclosed in ProLong Diamond Antifade Mountant (Thermofisher).
Slides were scanned using the PerkinElmer Vectra (v3.0; PerkinElmer). Spectral libraries were built from scans with single stained tissue for each reagent and used to unmix the multispectral images with the inForm Advanced Image Analysis software (inForm v2.3.0; PerkinElmer). The inForm software was then trained on several representative multispectral images, to perform tissue segmentation, cell segmentation, and phenotyping. All the settings from the training images were applied for batch analysis of the remaining images.
Multiplex immune gene expression
Nanostring nCounter technology was used to measure relative expression levels of immune genes within the tumor microenvironment on 27 samples. Total RNA (300ng) was assayed on an nCounter Digital Analyzer and hybridized to the Pan-cancer immune profiling panel, according to the manufacturer's instructions. The panel contained 770 genes, including key checkpoints, chemokines, cytokines, and associated control genes. The quality control and normalization of the data were done with nSolver. The measured expression values were normalized to the geometric mean of the housekeeping gene expression levels with the lowest coefficient of variation (%CV). Additionally, we used a custom-designed codeset for 48 major immune genes.
QUANTIFICATION AND STATISTICAL ANALYSIS
Somatic variant detection
Somatic single nucleotide variants (SNVs) were identified using two detection tools Mutect2 and VarScan2. To exclude the effect of coverage variability among the samples, we normalized the number of mutations by the number of bases with sufficient coverage (> 10X) per megabase on the reference genome. Despite the substantial mutational concordance between M08a and M08b, 16% (n = 32) of the coding mutations in M08a were not found in the consecutive sample, M08b.
Mutational signatures were defined based on each pair of reference-altered bases. Additionally, the number of transitions was calculated as the count of nucleotide changes purine -> purine and pyrimidine -> pyrimidine (e.g., A -> G), while transversions were considered the interchanges of purine and pyrimidine.
Driver mutations
Somatic nonsilent SNVs within known cancer genes (Ion AmpliSeqTM Cancer Hotspot Panel v2) were considered as driver events and used to classify the samples into two groups based on the number of events (0-1 versus R 2 driver events).
Copy number estimation
The read alignments from the Exome-seq data were used to identify amplified or deleted chromosomal regions, by correcting for GC content and comparing to the exome profile of a matched normal sample. Tumor ploidy, tumor purity, and allele-specific copy number quantification were called with Sequenza (v1.12) corresponding to the best fitting model from the data. The tumor purity estimates correlated with the rough estimations from H&E stained scans (r = 0.66 for P210 and r = 0.65 for P45). The copy number alterations per chromosome were also inferred from whole exome-sequencing data and visualized using the Python command-line software toolkit, CNVkit ( Figure 3A) . Additionally, subclonal allele-specific copy number identification and quantification were estimated using the algorithm from TitanCNA (v1.12) and used to examine the chromosome 4 region containing IL15 ( Figure 5B ).
Metastatic evolvogram
Phylogenetic tree Phylogenetic analysis of multi-site mutational profiles allowed discriminating conserved from late genetic events/mutations and answered which driver mutations occurred at which branches of progression. A phylogenetic tree was reconstructed using all nonsilent mutations to create a binary present/absence matrix as input to generate an unrooted tree with the parsimony ratchet method implemented in the R package phangorn. The function acctran determined the length of the branches proportionally to the number of nonsilent mutations (Figure 2A) .
The allele-specific copy number quantifications inferred with Sequenza were compared using the transducer-based pairwise comparison function implemented in MEDICC, and evolutionary distances between the samples were estimated to infer a phylogenetic tree ( Figure S1A) (Schwarz et al., 2014) . Both primary tumors were near-diploid, resulting with no copy-number trunks in the phylogenetic trees.
Inference of metastasis origin
For each pair of metastases, a score was inferred based on shared and unique coding SNVs. Precisely, the parent-child relationship was defined by the highest Jaccard similarity coefficient ( Figure 2B ). The percentage of shared coding and non-coding mutations was 18% in P210 and 16% in P45 ( Figure 1E ), most of which were shared between several metastases (17.6% in P210 and 22.9% in P45). In the case of the three samples in P210 for which exome-seq could not be performed, their origin was inferred from the shared hotspot mutations detected with targeted sequencing.
Tumor clonality and clonal inference
To resolve the clonal composition of each tumor sample, we estimated the fraction of tumor cells containing each mutation estimated with PyClone (v0.13.0) by integrating the variant allele frequencies of each mutation with the Sequenza-derived absolute parental copy number information and purity estimates ( Figures 3B and 3C) . Multisample analyses were performed in 50,000 iterations. Each tumor clone represents a cluster of mutations with similar variations in cellular prevalence across all samples. Clusters assigned with three or fewer mutations were considered underrepresented or artifacts from poorly called copy number, and they were excluded from the analysis. Similarly, only tumor clones with at least 10% clonality were considered.
A genetic algorithm was then applied for subclonal hierarchy inference from somatic mutations (SCHISM v1.1.2), to determine the parent clone for each tumor clone. Based on the tumor clone frequencies and the clonal hierarchy, the metastatic evolvogram was graphically represented using the R package FishPlot. The samples were ordered by detection time (numerical order used when multiple metastases were detected at the same time).
Inter-metastatic heterogeneity A mutational IMH index was calculated for each metastasis analogously to the intra-tumor heterogeneity (ITH) index, as the mean of the proportion of heterogeneous mutations relative to the total number of mutations determined by pairwise comparison of all metastases (Murugaesu et al., 2015) . Similarly, a copy number IMH index was derived by comparison of the copy number events.
HLA typing and mutation detection in HLA-I genes High-precision re-alignment of the sequenced reads against a full-length genomic library of all known HLA allele sequences (IMGT/HLA database), considering prior population-based allele frequencies yielded 4-digit HLA types for each normal sample. For neoantigen prediction, we used the HLA haplotype estimated for the normal sample. HLA typing was applied also on the primary tumor and all metastases for each patient. The haplotype definitions were confirmed continuously across all samples, except for some metastases in the patient P210 where the alleles HLA-B*40:1 and HLA-C*03:04 were not predicted due to loss of heterozygosity. Paired comparison of each tumor sample with the matched normal sample based on the re-aligned reads on HLA regions was used to detect high fidelity mutations in the highly polymorphic HLA genes, using the algorithm implemented in POLYSOLVER.
Loss of heterozygosity in HLA class I genes
We analyzed the raw exome-sequencing data of matched normal and tumor (primary and metastatic) samples, using the algorithm LOHHLA (McGranahan et al., 2017) . A loss of heterozygosity event was reported when a copy number lower than 0.5 was estimated using binning and B-allele frequency settings, and when the significance of allelic imbalance was reached (p < 0.01), counting each sequencing read once.
HLA-binding epitope prediction
Neo-epitopes were selected from the whole pool of 9-10mers with amino acid changes derived from the point mutations. Their binding affinity to the corresponding HLA-A, HLA-B, and HLA-C alleles was estimated with netMHCpan (v3.0). Absolute affinity values IC 50 % 500nM and relative percentile rank % 1% were the selection criteria for HLA binders. Peptides that matched to the human proteome (self-peptides) were removed (9.58%).
Metastasis and clonal immunoediting
We calculated an immunoediting score with modifications of a previously published method but tested our conclusions also using the original method, different selection criteria, and different reference sets for the expected neoantigens rate.
First, we determined the expected immunogenic rate using neoantigen predictions from 18 tumor types in The Cancer Genome Atlas (n = 8,458) . The expected rate of immunogenic mutations,B, was calculated independently of the mutation context as the average fraction of immunogenic mutations given a pool of coding mutations. The expected fraction of immunogenic mutations, B pred , for sample i with a set of coding mutations M i was calculated as:
Then, for each possible nucleotide change, we calculated the probability that its trinucleotide context would result with a nonsynonymous codon. We define P s as the probability that a trinucleotide pattern s results with a synonymous codon change. Given a set of coding mutations, M i and their corresponding mutation context, sðmÞ, in the sample i, the expected number of nonsynonymous mutations, was calculated as:
The immunoediting score represents the ratio of expected to observed immunogenic mutations per nonsilent mutation, for sample i: B obs;i N obs; i B pred;i N pred;i We demonstrated robust immunoediting score with regards to the reference set and selection criteria for neoantigens prediction. The results were consistent when using only CRCs from TCGA (n = 155) as a reference set. The division into edited and unedited did not change for any metastasis used in the statistical analysis ( Figure S4B ).
We also compared our results to the original method. First, using the pan-cancer dataset we derived the average number of immunogenic mutations per nonsilent mutation for each trinucleotide context, B s . For each spectrum s, the expected number of nonsilent mutations per silent mutation, N s , was estimated. Given a set of silent mutations, S i and their corresponding mutation context, sðmÞ, in the sample i, the expected number of nonsynonymous N pred;i and immunogenic mutations B pred;i were calculated as: Similarly, the immunoediting score represented the ratio of expected to observed immunogenic mutations per nonsilent mutation. The conclusions remained consistent with both versions of the method ( Figure S4C ).
Tumor clone immunoediting
Analogously to the immunoediting score for each metastasis, we calculated a score for each tumor clone based on the pool of mutations assigned to that clone. The tumor clones that had zero immunogenic mutations were assigned an immunoediting score of 1.
The calculated immunoediting scores did not appear to be related to the treatment response. Multiple lines of therapy were administered to the patients, loss of immunoedited clones was found following chemotherapy-based treatment (e.g., M4 in P210) and also in treatment-naive metastases (e.g., M10 in P210). Both immunoedited clones (e.g., clone 4 and 8 in P210) and immunoedited metastases (e.g., M10-b3 in P210) were observed independently of chemotherapy exposure. At the same time, absence of immunoediting could also be detected upon therapy response (e.g., M4, M5, M12 in P45).
The same approach and same selection criteria were applied for the analysis of the ovarian cancer and the CRC dataset. Furthermore, whether we considered only the expressed or all mutations, similar clonal immunoediting scores were observed (rho = 0.993, p < 2e-16).
Permutation-based null model and immunoediting scores cutoff
To prove that the immunoediting scores were lower than expected by chance, we randomly permuted all mutations within each patient (n = 1,000) preserving the number of mutations per sample to generate a sample-specific null model. Using the same method as with the real samples, we estimated an immunoediting score on the permuted samples. A p value was calculated for each sample as the fraction of observed values below its real-immunoediting score. A wide range of immunoediting scores were found below the value of 0.8 (immunoedited), whereas all other metastases (unedited) had similar scores above 0.8. Since all metastases with p < 0.1 had immunoediting score below 0.8 ( Figure S4A) , we chose the cutoff value of 0.8 to separate immunoedited from unedited metastases. In this way, edited metastases had significantly lower immunoediting scores compared to the distribution of permutation-based immunoediting scores following 1000 permutations of the coding mutations (p % 0.1).
Tumor clone groups
The tumor clones were separated into three groups. First, persistent tumor clones were defined as clones that were transmitted to at least one child metastasis and were present at the last branches of the respective phylogenetic subtree. To discriminate between clones that did not recur over a long period and more recent clones that also did not recur, we chose a cutoff of 4 years as the median follow-up time, starting from the primary tumor surgery date until the last follow-up (April 2016). If a tumor clone emerged within the last four years of the disease course and still hadn't recurred, it was assigned as Non-recurrent (%4Y). Finally, when a tumor clone did not disseminate for more than four years, it was defined as Eliminated (> 4Y), regardless of whether its harboring metastasis recurred or not. The groups Persistent and Eliminated (> 4Y) were then compared by the immunoediting status of the tumor clone using Fisher's Exact test, under the null hypothesis that immunoediting occurs with the same frequency in the two groups ( Figure 6A) .
Additionally, to demonstrate consistent and robust results, we also iterated through all possible year cutoffs ( Figure S2D ). At all cutoffs, immunoediting was significantly associated with eliminated clones (p < 0.0004). Furthermore, at any cutoff value starting from 2.23 years and above, immunoediting best separated eliminated from persistent clones (AUC > 0.88, higher than all other parameters).
Dn/Ds selective pressure score We compared positive selection of nonsynonymous mutations to selection of immunogenic mutations, using the Dn/Ds score. The Dn/Ds score represented the ratio of expected to observed nonsilent mutations per silent mutation. Specifically, we defined P s as the probability that a trinucleotide pattern s results with a synonymous codon change. Given a set of coding mutations, M ci and their corresponding mutation context, sðmÞ, in the clone c of sample i, the expected number of silent S pred;ci and nonsilent N pred;ci mutations is calculated as: Multispectral imaging and second order spatial statistics First-and second-order spatial analysis of multispectral imaging data was performed on reconstructed whole-slides, rather than separate analysis of each image that introduces edge effects and leads to loss of information. To identify the spatial point patterns of different phenotypes in the area of interest, we calculated a wide range of metrics, using the statistics environment R and particularly the package spatstat. The spatial co-localization of different immune cell types can be measured with the distances and number of mutual neighbors for each pair of cell phenotypes, as well as the distances to the nearest neighbors, and the nearest neighbor distance distribution function implementing edge-correction. Furthermore, second-order spatial statistics analysis was performed to describe the spatial organization of the tumor microenvironment. The function G(r) is the cumulative distribution of the distance from a typical random cell X to its nearest cell Y, where the argument r is the radius of the area in which G(r) is evaluated. The incorporated methods also enable distinguishing clustered or dispersed patterns compared to a random point process model. Deviations between the empirical G km (r) and theoretical G pois (r) curves suggest spatial segregation, shown in representative examples of the unedited groups (HiNo and LoNo, Figure 5G ).
Predictive model of metastasis evolution
A recurrent time-to-event model was developed with a multi-state approach (mstate) with two transitions, metastasis detection and metastasis recurrence. We estimated the probabilities of recurrence given a set of covariates, immunoediting, Immunoscore, and metastasis size. The covariates were selected for the model using the Akaike Information Criterion (AIC) and one-sample-out approach. Assuming time-dependent probabilities, we added a time variable to the model, Time from Detection (TFD). A cutoff of 2.05 years was the median of recurrence event time. Two independent datasets were used to verify the model. First, we compiled the data from a recently published case-study of one ovarian cancer patient with 4 metachronous metastases (all resected simultaneously several years after their detection) (Jimenez-Sanchez et al., 2017) . The immunoediting scores and metastasis volumes were reported in the study. Immunoscore percentiles were estimated using a larger ovarian cancer dataset as a reference (n = 212) (Zhang et al., 2018) . We applied our prediction model and we validated that the primary tumor had a high probability of recurrence. We also predicted high chances of recurrence of three out of four metastases after the resection time ( Figure S5 ). Regarding the second recurrence event, an important point to consider is that immunoediting and Immunoscore were measured several years after this event. Hence, the probabilities for the second prediction are based on the assumption that the Immunoscore and the immunoediting values were constant.
Second, we assumed that metastatic dissemination and progression is influenced by immune pressure in both metastatic and primary tumors. Hence, we analyzed primary CRC to predict the first event of metastatic dissemination. We obtained carefully curated clinical information on TCGA (Liu J et al. Cell 2018) and previously published immunoediting analyses of CRC (combined n = 132). First, we observed an association between immunoediting and decreased risk of metachronous recurrence (Figures S6A-S6C ). We used the published immunoediting scores (Yes/No), metastasis size (Hi = T3/T4, Lo = T1/T2), and an Immunoscore-like percentile derived from CD8A expression. For each tumor in the three groups of Immunoscore/ Immunoediting, we predicted the probability of recurrence within one year of the progression-free survival time. We separated the patients into high, medium, and low risk based on the probability quantiles at 1/3 and 2/3. The three groups were compared with Kaplan Meier curves and log-rank p values. Our prediction model significantly segregated low, intermediate and high metastatic recurrence risk ( Figure S6D ).
Statistics
Cox proportional hazard model for univariate and multivariate analyses was applied for first recurrence events. The AG-method implemented in the R package ''survival'' was applied for multiple recurrence events. Bivariate associations were examined with Spearman correlation tests (coefficient r). Adjustment of p values followed comparison of the two patients by multiple genomic parameters, comparison of the two tumor clone groups by several types of mutational parameters, comparison by spatial parameters for each cellular phenotype. Pairwise comparisons were used for the Immunoscore/immunoediting groups.
The metastasis sample derived from the consecutive slide was excluded from the statistical analysis and considered as a biological replicate. (B) Resection specimens were collected from a large necrotic area (M07n) and its surrounding tumor tissue in M07. Both areas harbored clone 2 (green), which was unedited. Additionally, clone 6 (blue) that originated from clone 2 was found uniquely in the necrotic area and exhibited evidence of immunoediting. (C) We combined the information from phylogenetic associations between the metastasis, their clonal composition, and the inference of clonal ancestry, to visualize the routes of metastatic spread in metastatic CRC. Some common clones could be detected in several synchronous metastases but not in the primary tumor, which could be a result of limited sampling of the primary tumor. Polyclonal seeding patterns are visualized, all of which appear to have occurred in direct clonal cooperation, except for one case of a temporally-separate wave of dissemination. The region M10-b3 had a different clonal origin from the remaining sites of the same metastasis, resulting from indirect clonal cooperation. (D) Immunoediting scores are plotted for each clone per metastasis. Different clones within the same metastasis have different scores. Unedited metastases had steady scores across time, whereas immunoedited metastases did not recur. * Clone 2 in the patient P45 (green) has only one immunogenic mutation that had negligible expression levels in public primary CRC datasets. Figure S3 . Immune Gene Expression Correlates with Immunoediting but Not with Mutational Load, Related to Figure 5 (A and B) Using multiplex gene expression on 770 genes associated with adaptive and immune response (Pan-cancer immune profiling panel, Nanostring), we focused on the genes representing T cells (CD8A, Th1, Tfh), cytokines, chemokines (CCL2), adhesion molecules, cytotoxic cells, and checkpoint molecules (Table S4 ). Their average expression was analyzed for correlation with TCRa diversity, immunoediting, number of immunogenic and unique, immunogenic mutations, and mutational load. The results were visualized with scatter plots and fitted linear regression lines (A) and contour plots (B) . Consistent findings were observed on the Nanostring panel with 48 genes. (Spearman correlation, ***p < 0.001, ** 0.001 R p < 0.01, * 0.01 R p < 0.05) Figure S4 . Robust Immunoediting Score, Related to STAR Methods (A-C) A permutation null model shows that the edited metastases have significantly lower immunoediting scores compared to a permutation-based distribution. All metastases with p < 0.1 have an immunoediting score below 0.8. The immunoediting score calculations remained robust with regards to the selection criteria (rank versus affinity & rank) (B) , the reference set for expected neoantigens rate (CRC versus Pan-cancer) (B) , and the modifications in the approach for expected neoantigen rate calculation (C) . Figure S5 . Clonal Immunoediting and Metastasis Recurrence in a Validation Dataset on Metastatic Ovarian Cancer, Related to Figure 6 (A and B) We compiled data from a recently published case-study of one ovarian cancer patient with 4 metachronous metastases (all resected simultaneously several years after their detection) (Jimenez-Sanchez et al., 2017) . None of the four metastases had a low Immunoscore and immunoediting (A). Using our approach, we estimated the clonal definitions (B) and calculated their clonal immunoediting scores. (C) Clones that were found in all metastases were unedited (p = 0.015), as opposed to clones that occurred sporadically in one or more metastases, AUC R 0.8. * Clone 2 (green) has only one immunogenic mutation. (D) We applied the prediction model using the Immunoscore derived from the IHC measurements provided in the study (Hi/Lo), the published immunoediting (Yes/No), and the reported metastasis volume (Hi/Lo). We predicted a high probability of 0.7 for the first recurrence of the primary tumor and a probability of around 0.25 for the primary tumor to recur at the second time of recurrence. Regarding the second recurrence event, an important point to consider is that immunoediting and Immunoscore were measured several years after this event. The probabilities for the second prediction are based on the assumption that the Immunoscore and the immunoediting values are constant. The model predicted that this ovarian cancer patient would likely have a recurrence originating from the vaginal cuff metastasis or spleen metastasis. 
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